Imunon (IMNN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Imunon (IMNN) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Imunon's market cap?
Imunon (IMNN) has a market capitalization of approximately $4M, trading at
What is Imunon's P/E ratio?
Imunon's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Imunon?
Imunon runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Imunon pay a dividend?
Imunon does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Imunon financially healthy?
Imunon carries a debt-to-equity ratio of 0.27x and a current ratio of 1.59x, with a market beta of 1.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Imunon a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Imunon (IMNN) the key facts are: market cap $4M, 52-week range 1.59-8.1913. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Imunon's full fundamentals live
Get Imunon's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.